Discloses the use of a product comprising: (a) a first immunogenic composition comprising (i) at least a first immunogen or an immunogenic fragment thereof, and (ii) a TLR4 agonist, and (b) a second immunogenic composition comprising a lentiviral vector comprising a nucleotide sequence that encodes the first immunogen or an immunogenic fragment thereof, wherein the lentiviral vector is incorporated into a vector particle, wherein the vector particle comprises a lentiviral vector genome and an alpha virus envelope； in the manufacture of a medicament in the treatment of a subject requiring the priming and boosting of an immune response to said first immunogen.
